Ingelheim am Rhein, Germany
Ingelheim am Rhein, Germany

Time filter

Source Type

News Article | February 15, 2017
Site: cen.acs.org

In 2014, Kim Janda of Scripps Research Institute California discovered that ONC201, a drug candidate under development at Oncoceutics, had been patented with an incorrect chemical structure. Scripps applied for a new patent on the compound with the correct structure and licensed it to another company, Sorrento Therapeutics. But this doesn’t mean the dispute is over. Janda argues that Scripps’s application for a composition-of-matter patent, which would grant rights to the molecule itself, would take precedence over Oncoceutics’s method-of-treatment patent, which grants rights to the molecule’s applications. In such cases, a company can’t legally profit from the use of a patent-protected substance without licensing it from its owner. Scripps’s patent is still under review. “This is an interesting saga, and it would seem freighted with money and emotion,” says intellectual property attorney Kendrew H. Colton of Fitch, Even, Tabin & Flannery LLP in Washington, D.C. The story of ONC201’s incorrect structure started in 1973, when pharmaceutical company Boehringer Ingelheim obtained a now-expired German patent on the compound, then called TIC10. The patent showed a structure with three central rings fused linearly. But the patent’s chemical recipe for making TIC10 produced a compound with one of the rings at an angle to the other two. The National Cancer Institute later included TIC10 and its incorrect linear structure in a compound database. A Pennsylvania State University group found TIC10 in the database and discovered that the agent, synthesized using the patent’s recipe to produce the nonlinear structure, had potent anticancer activity. Penn State patented TIC10 with the misassigned structure and licensed it to Oncoceutics, which renamed it ONC201. Janda then found the structural error, and Scripps applied for a new patent, sparking the current dispute. Oncoceutics has licenses to six ONC201-related patents. Five were issued in time to include the correct structure. The patent just reissued, the first in the series, was the only one with the wrong structure. Oncoceutics chief development officer Martin Stogniew replies that company officials “do not see any route for a valid composition-of-matter patent for the ONC201 structure” for Scripps because the molecule “was synthesized and disclosed in 1973” and the first ONC201 patent preceded Janda’s finding. In 2014, patent attorneys told C&EN that Scripps’s composition-of-matter patent could run into trouble because the institution had applied for it after others had made the critical discovery that ONC201 has anticancer activity, and because Penn State Research Foundation, the method-of-treatment patent holder, could have determined the structure correctly if it had realized it was wrong. As the legal battle continues, Oncoceutics has been moving ahead with testing ONC201 in six Phase I and Phase II trials against solid tumors, multiple myeloma, non-Hodgkin lymphoma, acute leukemia, and glioblastoma. The company is also developing two ONC201 analogs. Colton points out that in 2015 the U.S. Court of Appeals for the Federal Circuit upheld a patent with a corrected chemical structure. But if the Scripps patent is approved, he notes, Oncoceutics might be subject to Scripps’s composition-of-matter rights.


CrowdReviews.com Partnered with SMi to Announce: Boehringer Ingelheim Explore Overcoming Challenges to Industry in the Device Development Process at Asthma & COPD 2017 SMi will return to London once more for the 13th annual Asthma & COPD show taking place on the 29th & 30th March 2017. Stefan Leiner, Chemical-Pharmaceutical Expert from Boehringer Ingelheim will be speaking at this year’s event on "Overcoming challenges to industry in the device development process." Stefan will discuss: moving away from generic development, taking age group into consideration when developing a device; considerations for paediatric and elderly patients, incorporating clinical trials as a key step in obtaining device approval as well as USP regulatory updates on spacers in new devices. In the lead up to the event, SMi conducted a quick Q & A with Stefan to discuss the current landscape of the fields of asthma & COPD: "SMi: What do you see as the greatest hurdle to asthma and COPD treatments? Stefan: One hurdle is the complexity of inhalers: Inhalation therapy requires attentive patients. The second hurdle is the long-term treatment which triggers adherence problems. And thirdly, current therapies are not curing, todays therapies target symptoms, not the cause of the diseases. SMi: What should be done to address this? Stefan: We made some progress to make inhalers easier. However, a lot of research is needed to move to curing – we need new approaches." Inhalers will be just one of the topics discussed throughout the two days. Other talking points include: regulatory updates, formulation development, therapeutic developments, personalised treatments, biologics, biomarkers, COPD updates, The Salford Lung Study and so much more from respiratory experts from MHRA, GSK, Boehringer Ingelheim, Glenmark Pharmaceuticals, Janssen, Teva, AstraZeneca, MedImmune, Mylan, Imperial College of London, Actavis and many more. A CPD certified pre-conference workshop will be hosted alongside the conference by Cambridge Consultants on "The future of Asthma & COPD management; from connected inhalers to therapy management." For further information on the two day agenda or those wishing to attend, visit the event website on Asthma & COPD 2017 is sponsored by Vitalograph and Nemera. For sponsorship packages: Contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk For group delegate bookings: Contact Ameenah Begum on +44 (0)20 7827 6166 or email For media enquiries, contact Zoe Gale on +44 20 7827 6138 or 13th annual Asthma & COPD 29-30 March 2017 London, UK www.asthma-copd.co.uk/crowdreview Sponsored by Vitalograph and Nemera Contact e-mail: zgale@smi-online.co.uk Contact tel: +44 (0) 207 827 6166 #asthmacopdsmi About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Naples, FL, February 14, 2017 --( PR.com )-- The 2017 agenda will bring together senior scientists and respiratory and inhalation specialists to discuss ongoing challenges and explore leading strategies to novel treatments and solutions for these respiratory diseases.Stefan Leiner, Chemical-Pharmaceutical Expert from Boehringer Ingelheim will be speaking at this year’s event on "Overcoming challenges to industry in the device development process." Stefan will discuss: moving away from generic development, taking age group into consideration when developing a device; considerations for paediatric and elderly patients, incorporating clinical trials as a key step in obtaining device approval as well as USP regulatory updates on spacers in new devices.In the lead up to the event, SMi conducted a quick Q & A with Stefan to discuss the current landscape of the fields of asthma & COPD:"SMi: What do you see as the greatest hurdle to asthma and COPD treatments?Stefan: One hurdle is the complexity of inhalers: Inhalation therapy requires attentive patients. The second hurdle is the long-term treatment which triggers adherence problems. And thirdly, current therapies are not curing, todays therapies target symptoms, not the cause of the diseases.SMi: What should be done to address this?Stefan: We made some progress to make inhalers easier. However, a lot of research is needed to move to curing – we need new approaches."Inhalers will be just one of the topics discussed throughout the two days. Other talking points include: regulatory updates, formulation development, therapeutic developments, personalised treatments, biologics, biomarkers, COPD updates, The Salford Lung Study and so much more from respiratory experts from MHRA, GSK, Boehringer Ingelheim, Glenmark Pharmaceuticals, Janssen, Teva, AstraZeneca, MedImmune, Mylan, Imperial College of London, Actavis and many more.A CPD certified pre-conference workshop will be hosted alongside the conference by Cambridge Consultants on "The future of Asthma & COPD management; from connected inhalers to therapy management."For further information on the two day agenda or those wishing to attend, visit the event website on www.asthma-copd.co.uk/crowdreview Asthma & COPD 2017 is sponsored by Vitalograph and Nemera.For sponsorship packages: Contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.ukFor group delegate bookings: Contact Ameenah Begum on +44 (0)20 7827 6166 or email abegum@smi-online.co.uk For media enquiries, contact Zoe Gale on +44 20 7827 6138 or zgale@smi-online.co.uk 13th annual Asthma & COPD29-30 March 2017London, UKSponsored by Vitalograph and NemeraContact e-mail: zgale@smi-online.co.ukContact tel: +44 (0) 207 827 6166#asthmacopdsmiAbout SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk


News Article | February 22, 2017
Site: www.PR.com

Returning to Central London for the 14th year, SMi’s Controlled Release Delivery conference will take place on the 3rd & 4th of April 2017. London, United Kingdom, February 22, 2017 --( Hear from Merck, Novartis, Janssen, Actelion, GSK, Boehringer Ingelheim and many more as they evaluate: generic drug development, biopharmaceutical approaches, oral bioavailability and parenteral drug delivery. Keynote addresses for Controlled Release Delivery 2017: René Holm, Head and Scientific Director, Liquids & Parenterals, from Janssen will be presenting on "Lipid suspensions - how, when and with what?" René will discuss: - What is a lipid based suspension and how could it look from a commercialisation perspective? - When can lipid based suspensions be used to improve the oral bioavailability? - How large a proportion of the compound needs to be solubilised in the lipid phase? - What excipients to use for lipid based formulation? Mark Wilson, Director, Technology Licensing, PTS from GlaxoSmithKline will be speaking on "The development and commercialisation of drug delivery systems Challenges and opportunities," where he will provide attendees with information on the following: - GSK’s experiences in developing technologies - The collaborative “open innovation” approach - Commercialisation challenges – finding the breakthrough application - Examples of successful development and exploitation projects - GSK’s approach to working with other organisations A full speaker line-up and detailed conference agenda is available to download online at www.controlledreleasedelivery.com/prcom. For those looking to attend, there is currently a £100 discount available which expires on 28th February 2017. Controlled Release Delivery Strengthening innovation and overcoming the challenging regulatory landscape 3rd & 4th April 2017 London, UK Sponsored by: Avanti Polar Lipids, Buchi, Data Detection Technologies, Precision NanoSystems and Sirius Analytical www.controlledreleasedelivery.com/prcom Contact Information: For all media enquiries contact Zoe Gale on Tel: +44 (0)20 7827 6032 / Email: zgale@smi-online.co.uk To register for the conference, visit www.controlledreleasedelivery.com/prcom or contact Ameenah Begum for group bookings on Tel: +44 (0)20 7827 6166 / Email: abegum@smi-online.co.uk To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, February 22, 2017 --( PR.com )-- The two day conference will provide attendees with 5+ hours of networking time, an exclusive post-conference workshop and 16 thought provoking presentations covering the topics of; innovations in drug delivery; nanoparticles, nanomedicine & QbD, CNS drug delivery and therapeutic applications.Hear from Merck, Novartis, Janssen, Actelion, GSK, Boehringer Ingelheim and many more as they evaluate: generic drug development, biopharmaceutical approaches, oral bioavailability and parenteral drug delivery.Keynote addresses for Controlled Release Delivery 2017:René Holm, Head and Scientific Director, Liquids & Parenterals, from Janssen will be presenting on "Lipid suspensions - how, when and with what?" René will discuss:- What is a lipid based suspension and how could it look from a commercialisation perspective?- When can lipid based suspensions be used to improve the oral bioavailability?- How large a proportion of the compound needs to be solubilised in the lipid phase?- What excipients to use for lipid based formulation?Mark Wilson, Director, Technology Licensing, PTS from GlaxoSmithKline will be speaking on "The development and commercialisation of drug delivery systems Challenges and opportunities," where he will provide attendees with information on the following:- GSK’s experiences in developing technologies- The collaborative “open innovation” approach- Commercialisation challenges – finding the breakthrough application- Examples of successful development and exploitation projects- GSK’s approach to working with other organisationsA full speaker line-up and detailed conference agenda is available to download online at www.controlledreleasedelivery.com/prcom. For those looking to attend, there is currently a £100 discount available which expires on 28th February 2017.Controlled Release DeliveryStrengthening innovation and overcoming the challenging regulatory landscape3rd & 4th April 2017London, UKSponsored by: Avanti Polar Lipids, Buchi, Data Detection Technologies, Precision NanoSystems and Sirius Analyticalwww.controlledreleasedelivery.com/prcomContact Information:For all media enquiries contact Zoe Gale on Tel: +44 (0)20 7827 6032 / Email: zgale@smi-online.co.ukTo register for the conference, visit www.controlledreleasedelivery.com/prcom or contact Ameenah Begum for group bookings on Tel: +44 (0)20 7827 6166 / Email: abegum@smi-online.co.ukTo sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.ukAbout SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


Research and Markets has announced the addition of the "Global Pharmaceutical Fine Chemicals Market Analysis & Trends - Industry Forecast to 2025" report to their offering. This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. Some of the prominent trends that the market is witnessing include companies producing fine chemicals are making efforts towards development of efficient products, technological advancements in production procedures, expansion in the pharmaceutical industry in emerging regions and growth opportunities/investment opportunities. Based on Chemicals the market is categorized into big molecules and small molecules. Based on Type of Drug the market is categorized into non proprietary drugs and poprietary drugs. As per Therapeutic Use the market is segmented into respiratory gastrointestinal, mucoskeletal, diabetes, metabolic system, cardiovascular, infectious diseases, neurological, oncological and other therapeutic uses. Report Highlights: - The report provides a detailed analysis on current and future market trends to identify the investment opportunities - Market forecasts till 2025, using estimated market values as the base numbers - Key market trends across the business segments, Regions and Countries - Key developments and strategies observed in the market - Market Dynamics such as Drivers, Restraints, Opportunities and other trends - In-depth company profiles of key players and upcoming prominent players - Growth prospects among the emerging nations through 2025 - Market opportunities and recommendations for new investments Key Topics Covered: 1 Market Outline 2 Executive Summary 3 Market Overview 3.1 Current Trends 3.1.1 Companies Producing Fine Chemicals are Making Efforts towards Development of Efficient Products 3.1.2 Technological Advancements In Production Procedures 3.1.3 Expansion in the Pharmaceutical Industry in Emerging Regions 3.1.4 Growth Opportunities/Investment Opportunities 3.2 Drivers 3.3 Constraints 3.4 Industry Attractiveness 4 Pharmaceutical Fine Chemicals Market, By Chemical 4.1 Big Molecules 4.2 Small Molecules 5 Pharmaceutical Fine Chemicals Market, By Type of Drug 5.1 Non Proprietary Drugs 5.2 Poprietary Drugs 6 Pharmaceutical Fine Chemicals Market, By Therapeutic Use 6.1 Respiratory 6.2 Gastrointestinal 6.3 Mucoskeletal  6.4 Diabetes 6.5 Metabolic System 6.6 Cardiovascular 6.7 Infectious Diseases 6.8 Neurological 6.9 Oncological 6.10 Other Therapeutic Uses 7 Pharmaceutical Fine Chemicals Market, By Geography 8 Key Player Activities 8.1 Mergers & Acquisitions 8.2 Partnerships, Joint Venture's, Collaborations and Agreements 8.3 Product Launch & Expansions 8.4 Other Activities 9 Leading Companies 9.1 Abbott 9.2 Akzo Nobel N.V 9.3 Albemarle Corporation 9.4 AstraZeneca 9.5 BASF SE 9.6 Boehringer Ingelheim GmbH 9.7 Clariant AG 9.8 Eastman Chemical Company 9.9 Evonik Industries 9.10 GlaxoSmithKlein 9.11 Lonza Group Ltd 9.12 Merck and co. 9.13 Roche 9.14 Royal DSM N.V. 9.15 The Dow Chemical Company For more information about this report visit http://www.researchandmarkets.com/research/4t3ktc/global


Sarasota, FL, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Myocardial Infarction Treatment Market by Product type (Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor blockers, Analgesics, Thrombolytics); Distribution channel (Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores); and Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022”. According to the report, global Myocardial Infarction Treatment Market was valued at approximately USD 1206.5 million in 2016 and is expected to generate revenue of around USD 1726.3 million by end of 2022, growing at a CAGR of around 6.1% between 2017 and 2022. Myocardial infarction or heart attack is caused due to blockage in the supply of oxygen-rich blood to heart muscles, resulting in permanent heart muscle injury and death of cells. The blockage is due to atherosclerosis, a process in which the plaque (fatty patches) is formed on the inside wall of the coronary artery or one of its smaller branches. If the plaque is ruptured, the blood clot is formed inside the artery blocking the blood flow. People with risk factors such as smoking, dyslipidemia, diabetes are more prone to myocardial infarction. Browse through 29 Market Tables and 31 Figures spread through 110 Pages and in-depth TOC on “Global Myocardial Infarction Treatment Market: By product, Distribution, Type, Size, Share, Analysis, Segment and Forecast 2016 – 2022”. Global Myocardial Infarction Treatment market is primarily driven by growing incidences of cardiovascular diseases and changes in lifestyle. Other major driving factors are risk factors such as obesity, hypertension, diabetes, reduced physical activity, and rise in a number of smokers. As per WHO, the risk of myocardial infarction is increased in smokers than non-smokers. However, the high price of drug research and development and stringent regulatory policies coupled with high cost of clinical trials may pose the challenge to myocardial infarction treatment market. Nevertheless, increase in acceptance of newer treatment technologies by emerging nations and technology breakthroughs are expected to act new avenues for myocardial infarction treatment market in near future.   The Myocardial Infarction Treatment market is segmented on the basis of different product type including Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor blockers, Analgesics, Thrombolytics. Analgesics and antiplatelet agent segments are expected to grow at the fastest rate during the forecast period. Browse the full "Myocardial Infarction Treatment Market by Product type (Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor blockers, Analgesics, Thrombolytics); Distribution channel (Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores); and Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022" report at https://www.zionmarketresearch.com/report/myocardial-infarction-treatment-market The myocardial infarction treatment market is segmented based on distribution channel into Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores. Based on geography, the myocardial infarction treatment market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. North America represents developed regional markets for myocardial infarction treatment market and is expected to see the rapid growth in the years to come. The U.S. is by far the leading myocardial infarction treatment market by country in North America. The U.S. market is expected to grow at the highest CAGR during the forecast period. This growth is mainly due to the growing incidences of cardiovascular diseases, obesity, and smokers. Moreover, other risk factors such as hypertension, diabetes, and dyslipidemia are very high in this region which promotes the growth of myocardial infarction treatment market. Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/myocardial-infarction-treatment-market Europe was the second largest regional market and is expected to show significant growth in the years to come. This growth is mainly due to increase in a number of patients diagnosed with hypertension. As per WHO, cardiovascular disease (CVD) causes more than half of all deaths across the European region. Asia-Pacific is expected to witness the fastest growth in the near future. Increasing geriatric population is the major driving factor along with lifestyle changes, physical inactivity and increasing prevalence of diabetes. However increased awareness of such life-threatening diseases may impact the market share. Latin America and Middle East & Africa market will be potential market due to increased awareness and adoption of newer myocardial infarction treatment. Thus, all the aforementioned parameters are expected to propel the market growth in this region. Some of the key players in Myocardial Infarction Treatment market include Bayer, Novartis, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, Sandoz, Astrazeneca, Janssen Biotech, Inc., Merck & Co. Inc., Sanofi, Pfizer Inc. among others. For more inquiry contact our sales team @ sales@zionmarketresearch.com This report segments the global Myocardial Infarction Treatment market as follows: Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.


Dublin, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market" report to their offering. This publication on "Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market" provides a comprehensive analysis of the anticoagulants market. The report includes the cumulative revenue generated by the market players from the sales of anticoagulants, including both generic and patented drugs at manufacturer's price and market share contributed by the sales of heparin, NOACs, Vitamin K Antagonists, and Injectable Direct Inhibitors in the total anticoagulants market. Further, the market in the study is differentiated on the basis of route of administration into oral and injectable. The market is also segmented by four geographical regions across the globe - North America, Europe, Asia Pacific, and Rest of the World. Detailed snapshot on key regions of the Market which includes North America, Europe, and Asia Pacific is included in the report to elucidate facts about the market in detail. The study also highlights the detailed information about major drug manufacturers in the global anticoagulants market and their respective shares by revenue in 2015. Analysis on patented drugs available in the market, and their approval procedure, timeline, and expected expiries is provided in report to assist new entrants in understanding the market before investing in the market. Various marketing analysis factors such as trends and developments and Porter's five forces analysis are also added in the study for clear understanding about the factors responsible for present scenario of the market. The future analysis of overall global anticoagulants market has also been discussed along with recommendations from analyst view. Key Topics Covered: 1. Executive Summary 2. Research Methodology 3. Introduction to Anticoagulants Uses Side Effects of Anticoagulants 4. Value Chain Analysis of Global Anticoagulants Market 5. Global Anticoagulants Market Size, 2013 - 2015 6. Global Anticoagulants Market Segmentation 6.1. By Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors), 2015 6.1.1. Heparin Market Segmentation by Type (Unfractionated and Low Molecular Weight Heparin) 6.1.2. NOACs Market Segmentation by Type (Rivaroxaban, Apixaban, Dabigatran Etexilate, and Edoxaban) Drug Approval Timelines Patent Expiries 6.2. By Route of Administration (Oral and Injectables) 6.3. By Geographical Regions (North America, Europe, Asia Pacific, and Rest of the World) 7. Snapshot on North America Anticoagulants Market By Countries (US and Canada) 7.1. US Market Indicators 7.1.1. US Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) 7.1.2. Key Anticoagulants in US 7.1.3. Regulatory Landscape New Drug Approval Procedure New Drug Timeline Generic Drug Approval Procedure Patents Exclusivity Anticoagulants Reimbursement Scenario in the US 7.2. Canada Market Indicators 7.2.1. Canada Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) 7.2.2. Cost of Key Anticoagulants in Canada 7.2.1. Market Share of Major Players (Bayer Inc., Boehringer Ingelheim, and Bristol-Myers Squibb Canada Co) in Canada Anticoagulants Market, 2015 7.2.2. Regulatory Landscape Generic Drug Approval Procedure Patents and Exclusivity Pharmaceutical Pricing and Reimbursement in Canada 8. Snapshot on Europe Anticoagulants Market 8.1. By Countries (Germany, France, Spain, Italy, UK, and Rest of the Europe) 8.2. Europe Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) 8.2.1. Cost of Key Anticoagulants in Europe 8.3. Europe Anticoagulants Market by Companies (Bayer Inc., Boehringer Ingelheim, Pfizer, and Others) 8.4. Regulatory Landscape 8.4.1. New Drug Approval Procedure 8.4.2. Patents 8.4.3. Reimbursement Scenario in Europe 9. Snapshot on Asia Pacific Anticoagulants Market By Countries (Japan, Australia, China, India, and Rest of the Asia Pacific) 9.1. Japan Market Indicators 9.1.1. Japan Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) 9.1.2. Key Anticoagulants in Japan 9.1.3. Regulatory Landscape New Drug Approval Procedure Patents 9.2. Australia Market Indicators 9.2.1. Australia Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) 9.2.2. Cost of Key Anticoagulants in Australia 9.2.3. Regulatory Landscape New Drug Approval Procedure Patents Reimbursement Scenario in Australia 9.3. China Market Indicators 9.3.1. China Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) 9.3.2. Cost of Key Anticoagulants in China 9.3.3. Market Share of Major Players (Bayer China, Boehringer Ingelheim, and Others) in China Anticoagulants Market, 2015 9.3.4. Regulatory Landscape New Drug Approval Procedure Patents 9.4. India Market Indicators 9.4.1. India Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) 9.4.1. Cost of Key Anticoagulants in India 9.4.2. Market Share of Major Players (Bayer India, Boehringer Ingelheim, Pfizer, GSK Pharmaceutical Ltd., Aventis Pharma and Others) in India Anticoagulants Market 9.4.3. Regulatory Landscape New Drug Approval Procedure Patents Pricing and Reimbursement Scenario in India 10. Porter's Five Forces Analysis for Global Anticoagulants Market 11. Trends and Developments in Global Anticoagulants Market 11.1. Expanding Therapeutic Indication 11.2. High incidence rate of DVT/PE 11.3. Disadvantages of Patented NOACs over Generic VKAs and Heparin Impacting Market Negatively 12. Global Anticoagulants Market Competitive Landscape 12.1. Market Share of Key Players in Global Anticoagulants Market, 2015 12.2. Company Profiles for Key Manufacturers in Anticoagulants Market 12.2.1. Sanofi 12.2.2. Pfizer Inc. 12.2.3. Boehringer Ingelheim 12.2.4. Bayer AG 12.2.5. Bristol-Myers Squibb Company 12.2.6. Daichi Sankyo company, Limited 13. Future of Global Anticoagulants Market 13.1. Future Outlook and Projections, 2016 - 2020 14. Analyst Recommendations 15. Macroeconomic Indicators 15.1. Aging Population 15.2. Deaths from Cardiovascular Diseases, 2010 - 2020 15.3. Healthcare Spending, 2010 - 2020 For more information about this report visit http://www.researchandmarkets.com/research/2cpzv5/global


INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today a new collaboration with Vanderbilt University, Nashville, Tennessee. The multi-year program complements an already existing collaboration by focusing on the research and development of small molecule compounds targeting the protein SOS (Son Of Sevenless). This molecule activates KRAS, a molecular switch that plays a central role in the onset of some of the deadliest cancers. The collaboration combines pioneering research in the laboratory of Stephen W. Fesik, Orrin H. Ingram II professor in cancer research at Vanderbilt University, with the unique expertise and strength of Boehringer Ingelheim in drug discovery and clinical development. The new collaboration adds to an ongoing joint project with Vanderbilt University initiated in 2015 that achieved two major milestones by identifying lead compounds that bind to KRAS with high affinities. These discoveries raise the prospect of developing novel cancer treatment options based on molecules that are able to block this critical cancer driver. “We are very encouraged by the successful identification of inhibitors of KRAS in our alliance with Professor Fesik and his team at Vanderbilt University and look forward to expanding our collaboration,” said Clive R. Wood, Ph.D., senior corporate vice president, discovery research at Boehringer Ingelheim. “With new technologies and the scientific discoveries made by Professor Fesik’s laboratory, we believe the time is now right to step up research efforts to develop novel cancer treatments that work by attacking KRAS and associated signaling pathways.” “Professor Fesik is a pioneer in the discovery of small molecules that bind to and inhibit challenging drug target proteins. His partnership with Boehringer Ingelheim will expedite efforts to discover novel cancer treatments that work on KRAS,” said Lawrence J. Marnett, Ph.D., the Mary Geddes Stahlman professor of cancer research, university professor of biochemistry and chemistry and dean of basic sciences for the Vanderbilt University School of Medicine. Mutations in the genes that encode KRAS are among the most powerful and frequent cancer drivers. They contribute to some of the most aggressive and deadly cancers, including up to 25 percent of lung, 35-45 percent of colorectal and about 90 percent of pancreatic tumors. KRAS has been a particularly difficult protein to target and no effective treatments targeting KRAS have been developed since its discovery in human cancers more than 30 years ago. The development of the first molecules inhibiting KRAS activation promises huge potential for the development of improved cancer therapies, which would offer treating physicians unprecedented options to complement existing treatment regimens. By researching multiple approaches including direct inhibition of KRAS and indirect inhibition via SOS, Boehringer Ingelheim aims to accelerate the discovery of novel targeted therapies. The new collaboration with Vanderbilt University further strengthens Boehringer Ingelheim’s oncology pipeline, which focuses on tumor cell-directed cancer treatments, new approaches in immune oncology and their combinations. It underscores the companies’ commitment to pioneering emerging fields of research and working closely with its partners to accelerate the development of novel first-in-class, breakthrough medications that fit the needs of patients, caregivers and healthcare professionals. For references and notes to editors, please visit:


Patent
Boehringer Ingelheim GmbH | Date: 2012-11-14

The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.


Patent
Vectura Delivery Devices Ltd and Boehringer Ingelheim GmbH | Date: 2014-09-11

A passive inhaler for delivery of a powder-form inhalation formulation from a blister strip with a plurality of blister pockets is proposed. The inhaler comprises an impaction element onto which the air stream can impact together with entrained inhalation formulation for better deagglomeration. Alternatively, the inhaler comprises an oscillating and/or vibrating device for better de-agglomeration of the inhalation formulation. Alternatively or additionally, the inhaler comprises one or two mixing means for generating swirls, preferably with opposite rotation directions.


Patent
Boehringer Ingelheim GmbH | Date: 2013-05-17

The invention relates to a system composed of an inhaler and a capsule, preferably intended for single use. The capsule contains a preferably powdered pharmaceutical preparation which, for inhalation, is expelled from the capsule through at least one hole. The capsule comprises as capsule elements a capsule cap and a capsule body, at least one of which comprises at least one prefabricated hole. The prefabricated hole in the capsule is sealed off in the transporting state of the system and is open in the usage state. The hole is exposed by actuation of a pulling mechanism. Prior to this the hole is closed off by a capsule receptacle or a film. In one embodiment the capsule may be present in two different states, for example in different insertion positions of the capsule elements. In the first state the prefabricated hole is closed off and in the second it is exposed. Also shown is an inhaler suitable as a disposable product, which is manufactured from thermoformed parts or from blister film.

Loading Boehringer Ingelheim GmbH collaborators
Loading Boehringer Ingelheim GmbH collaborators